Member Info for Babbler2

Note the 5 code... Probably move it to 5 tomorrow before retrace.

"only" quad bagged if you look at first trades.

No idea what they do. However may 2015 they were 5.5p.

Tbh mate... I didn't go in and I saw the rns. No idea why it rose so much. Must be historic.

That is what put me off... they dont rns much here... so no share drivers... need better pr.

missed the chance at 10p... oh well...

only thing putting me off here is the results werent great... huge potential though and show this week could lead to new customers. Shame they didnt rns the news...

Old news? It has todays date on it!!

interesting... woken up it seems... lots of 1mil chunks... placing forward selling? dont know anything about them but may have a punt.

damn it... was going to buy in yesterday - work got in the way :(

Another rns - home power trial... nice.

Sorry one of my tips for you this morning moved faster than expected. Up 80 % at one point. Didn't expect news so soon lol.

It means the price has gone above yesterdays close price... not the case here it seems... but nice long hold.

not one to buy imo...

interesting open offer @ a lot higher than yesterdays close?

looking good... full ask paid.

No worries... just remember to RESEARCH and not buy on my say so lol...

MrCalm... there are a few good ones around... just a case of timing... emh, ctag (consolidated nicely pre next move), irr (near low), AXM (low - but high risk for 10 to 20%), NYO (will move eventually), TLOU, VELA (patience required!), COS (one of my favourites but again patience required). And here... but watch this one as low volume usually... and rose quite a bit on news. GL.

I will post in my main one in next 2 mins or so - click my name :)

Not for me thanks :). Im in plenty of short term puts already which could double over next 2 weeks lol From May RNS: Dr Stephen Franklin, Chief Executive Officer of Evgen Pharma, said: "I am very pleased with the significant progress the Company has made since joining AIM in October last year. We are already treating patients in a Phase II trial of our lead product, SFX-01, in subarachnoid haemorrhage and we are fully funded to complete a Phase II trial in breast cancer which will begin later this year. These two trials represent significant value inflexion points for Evgen Pharma. "In addition, we are expecting results later this year of a head-to-head preclinical study of SFX-01 against Tecfidera®, the market leading oral treatment for the relapsing form of multiple sclerosis."